Ultrasound in Evaluating Muscle-Glycogen Content in Cancer Patients

Sponsor
M.D. Anderson Cancer Center (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03982082
Collaborator
National Cancer Institute (NCI) (NIH)
21
1
1
44.6
0.5

Study Details

Study Description

Brief Summary

This trial studies how well an ultrasound procedure (non-invasive MuscleSound technology) can be used to learn about levels of glycogen (a type of sugar) in cancer patients during inpatient rehabilitation. The ultrasound information will be processed to represent the energy storage in the muscle. The energy storage in the muscle may help future research to look for dietary plans that can help to increase energy storage, patient exercise tolerance, and functional improvement.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Physical Therapy
  • Other: Questionnaire Administration
  • Procedure: Ultrasound
N/A

Detailed Description

PRIMARY OBJECTIVES:
  1. Determine feasibility of using non-invasive MuscleSound technology to determine glycogen stores in cancer patients.
EXPLORATORY OBJECTIVES:
  1. Determine the baseline glycogen storage in two different groups of cancer patients, who are undergoing inpatient rehabilitation: (1) those with cachexia; (2) those without cachexia.

  2. Determine the rate of depletion of muscle-glycogen stores by calculating the "Fuel Rating" score (FRS) at baseline, after 10-min of exercise and then again after 20-min of exercise.

  3. Determine if there is any correlation between muscle-glycogen (at baseline and its depletion rate over time) and other factors including cancer type, cancer stage, patient age, patient sex, current body mass index (BMI), presence or absence of cachexia, functional measures and patient reported outcomes.

OUTLINE:

Patients undergo ultrasound via MuscleSound technology over 3 minutes at baseline and immediately after each of 2 physical therapy sessions comprising cycling or walking over 10 minutes.

Study Design

Study Type:
Interventional
Actual Enrollment :
21 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Device Feasibility
Official Title:
Feasibility Study of Ultrasound to Evaluate Muscle-Glycogen Content in Patients With Cancer
Actual Study Start Date :
Apr 12, 2019
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Device feasibility (MuscleSound technology)

Patients undergo ultrasound via MuscleSound technology over 3 minutes at baseline and immediately after each of 2 physical therapy sessions comprising cycling or walking over 10 minutes.

Procedure: Physical Therapy
Undergo physical therapy
Other Names:
  • Physiatric Procedure
  • Physical Medicine Procedure
  • Physical Therapeutics
  • Physical Therapy Procedure
  • Physiotherapy
  • Physiotherapy Procedure
  • PT
  • Other: Questionnaire Administration
    Ancillary studies

    Procedure: Ultrasound
    Undergo ultrasound via MuscleSound technology

    Outcome Measures

    Primary Outcome Measures

    1. Glycogen Storage Assessment [Within 30 minutes of consent]

      Muscle-glycogen status will be assessed using ultrasound and MuscleSound® technology which generates an average FRS (Fuel Rating Score)

    Other Outcome Measures

    1. Functional Independent Measure [At baseline]

      The FIM (Functional Independent Measure) score will be collected retrospectively from the patient's medical record as this is performed by a nurse or therapist. This measure provides a measurement for assessing how much assistance is required for the patient to complete activities of daily living.

    2. Cancer characteristics of the patient [At baseline within 30 minutes of consent]

      Type of cancer, stage of cancer; past and present treatment

    3. Patient reported outcomes [At baseline]

      Patient-Generated Subjective Global Assessment (PG SGA-SF) Patient Reported Outcomes is a tool used to measure risks for malnutrition.

    4. Patient reported outcomes [At baseline]

      Edmonton Symptom Assessment Scale (ESAS) is a validated tool for regular assessment of symptom distress in the Rehabilitation setting. Patients are asked to grade severity of their symptoms from "no symptom" 0 to "worst symptom" 10 in the last 24 hours. ESAS has high test-retest reliability of (>0.8) and has been validated in many clinical settings including cancer patients.

    5. Body Composition [At baseline]

      Will be accessed using the bioimpedance machine to measure body fat and muscle mass.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Participants are willing and able to give written informed consent and to comply with study procedures.

    • Patients with a biopsy-confirmed solid malignant neoplasm with at least one neurologically-intact lower extremity, who fit into one of the following groups:

    • Group 1: Patients with cachexia, defined by loss of > 5% of body weight over the preceding 6-months (in absence of simple starvation defined as intentional weight loss) or weight loss > 2% with BMI < 20.

    • Group 2: Patients without cachexia, as defined above.

    • Patients who have a record of weight or BMI over preceding 6-months.

    • Patients must be receiving rehabilitation that includes exercise under the direction of a physical therapist.

    Exclusion Criteria:
    • Non-English speaking patients.

    • Patient with neurological compromise of both lower extremities causing muscle atrophy.

    • Underlying unstable medical condition (i.e: cardiac, pulmonary, or hematological) or musculoskeletal injury, which in the opinion of the investigator, limits participation in exercise of the measured lower extremity.

    • Patients who are unable to understand or follow through with study instructions.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 M D Anderson Cancer Center Houston Texas United States 77030

    Sponsors and Collaborators

    • M.D. Anderson Cancer Center
    • National Cancer Institute (NCI)

    Investigators

    • Principal Investigator: Ying Guo, MD, M.D. Anderson Cancer Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    M.D. Anderson Cancer Center
    ClinicalTrials.gov Identifier:
    NCT03982082
    Other Study ID Numbers:
    • 2018-1180
    • NCI-2019-02281
    • 2018-1180
    First Posted:
    Jun 11, 2019
    Last Update Posted:
    May 4, 2022
    Last Verified:
    Apr 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 4, 2022